CanadianCannabisWire LimeLight of The MONTH is
 

Lexaria Bioscience Corp.
(NASDAQ: LEXX)

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 26 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

Investment Considerations

• Lexaria Bioscience Corp. has disruptive proprietary technology protected by a broad international patent portfolio.
• The company has been issued 26 patents in the U.S., European Union and other countries, with more than 50 patents pending around the world.
• Lexaria’s DehydraTECH technology has a vast worldwide, multi-billion-dollar total addressable market, including multiple rapid-growth segments like cannabinoid and noncombustible nicotine delivery.
• The company has licensed its fat-soluble active molecule delivery technology to multiple established companies for use in their products.
• Lexaria completed an uplisting to Nasdaq Capital Markets and an $11 million financing in January 2021.

Recent Coverage:
 

InvestorNewsBreaks - Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND Program

August 10, 2022 8:45 AM

• Significant Milestone Achieved in Commercial Product Development Program
• Abbreviated 505(b)(2) Strategy Confirmed as an Appropriate NDA Pathway

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of a positive full written response from the Food and Drug Administration (“FDA”) from its pre-Investigational New Drug (“Pre-IND”) meeting regarding DehydraTECH-CBD for the treatment of hypertension. According to the update, the FDA confirmed agreement with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway for its program. This is advantageous because the abbreviated pathway, as it is often described, typically enables a faster route to commercial approval than the traditional 505(b)(1) NDA pathway. “We are very pleased to have received comments from the FDA toward opening our IND program and we will be executing FDA-confirmed IND-enabling work immediately,” said John Docherty, president of Lexaria Bioscience Corp. “We were delighted that our proposals were very well received by the FDA and the feedback received will be very helpful in compiling and filing our IND application as the next major regulatory step we are focused on moving forward.”

Receive SMS Text Alerts from CanadianCannabisWire

Text "CCWIRE" to 844-397-5787

(US Mobile Phones Only)

Featured Event

Grow Up Conference
9/12 - 9/14 – Niagara Falls, ON

Join us in spectacular Niagara Falls, ON for 3 days of cannabis cultivation and extraction.

Join top growers, suppliers, manufacturers, extraction equipment/services, hundreds of top speakers/keynotes and thousands of delegates together to bring you up-to-date on proven methods, innovations and technology. This year’s expo will include the Grow Up Extraction Zone.

Learn from over 100 cannabis cultivation and extraction experts at our 3 day conference.

Grow Up Conference and Expo is focused on the education, collaboration and growth of the cannabis growing industry. Meet licensed producers, suppliers, equipment manufacturers, investors, lawyers, government officials and growing enthusiasts – all in one magnificent location.

Meet old friends and create new relationships at Grow Up's famous Meet the Exhibitors networking party.

Upcoming Events

• NECANN’s New Jersey Convention — Atlantic City, NJ — 10/1 - 10/2
• NECANN's Maine Convention — Portland, ME — 10/15 - 10/16
• Alternative Products Expo, Chicago — Chicago — 11/3 - 11/5

About CanadianCannabisWire (CNW)

CanadianCannabisWire (CCW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and writers, CCW introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, CCW's innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. CCW is where news, content and information converge.